Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement by Chen, Ronald C. et al.
Active Surveillance for the Management of Localized Prostate Cancer
(Cancer Care Ontario Guideline): American Society of Clinical
Oncology Clinical Practice Guideline Endorsement
Chen, R. C., Bryan Rumble, R., Andrew Loblaw, D., Finelli, A., Ehdaie, B., Cooperberg, M. R., ... Jain, S. (2016).
Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline):
American Society of Clinical Oncology Clinical Practice Guideline Endorsement. Journal of Clinical Oncology,
34(18), 2182-2190. DOI: 10.1200/JCO.2015.65.7759
Published in:
Journal of Clinical Oncology
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2016 by American Society of Clinical Oncology.
This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:06. Nov. 2017
JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E
Author afﬁliations appear at the end of this
article.
Published online ahead of print at
www.jco.org on February 16, 2016.
Clinical Practice Guideline Committee
approval: November 2, 2015.
Editor’s note: This American Society of
Clinical Oncology Clinical Practice
Guideline Endorsement provides
recommendations based on the review
and analysis of the relevant literature in
the Cancer Care Ontario Active
Surveillance for the Management of
Localized Prostate Cancer Clinical
Practice Guideline. Additional information,
which may include methodology and data
supplements, slide sets, patient versions,
frequently asked questions, and other
clinical tools and resources, is available at
www.asco.org/endorsements/
ActiveSurveillance and www.asco.org/
guidelineswiki.
Authors’ disclosures of potential conﬂicts
of interest are found in the article online at
www.jco.org. Author contributions are
found at the end of this article.
Corresponding author: Suneil Jain, MD,
PhD, c/o American Society of Clinical
Oncology, 2318 Mill Rd, Suite 800,
Alexandria, VA 22314; e-mail: guidelines@
asco.org.
© 2016 by American Society of Clinical
Oncology
0732-183X/16/3418w-2182w/$20.00
DOI: 10.1200/JCO.2015.65.7759
Active Surveillance for the Management of Localized Prostate
Cancer (Cancer Care Ontario Guideline): American Society
of Clinical Oncology Clinical Practice Guideline Endorsement
Ronald C. Chen, R. Bryan Rumble, D. Andrew Loblaw, Antonio Finelli, Behfar Ehdaie, Matthew R. Cooperberg,
Scott C. Morgan, Scott Tyldesley, John J. Haluschak, Winston Tan, Stewart Justman, and Suneil Jain
A B S T R A C T
Purpose
To endorse Cancer Care Ontario’s guideline on Active Surveillance for theManagement of Localized
Prostate Cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of pro-
cedures for endorsing clinical practice guidelines developed by other professional organizations.
Methods
The Active Surveillance for the Management of Localized Prostate Cancer guideline was reviewed
for developmental rigor by methodologists. The ASCO Endorsement Panel then reviewed the
content and the recommendations.
Results
The ASCO Endorsement Panel determined that the recommendations from the Active Surveillance
for the Management of Localized Prostate Cancer guideline, published in May 2015, are clear,
thorough, and based upon the most relevant scientiﬁc evidence. ASCO endorsed the Active
Surveillance for the Management of Localized Prostate Cancer guideline with added qualifying
statements. The Cancer Care Ontario recommendation regarding 5-alpha reductase inhibitors was
not endorsed by the ASCO panel.
Recommendations
For most patients with low-risk (Gleason score# 6) localized prostate cancer, active surveillance is the
recommended disease management strategy. Factors including younger age, prostate cancer vol-
ume, patient preference, and ethnicity should be taken into account when making management
decisions. Select patientswith low-volume, intermediate-risk (Gleason 31 45 7) prostate cancermay
be offered active surveillance. Active surveillance protocols should include prostate-speciﬁc antigen
testing, digital rectal examinations, and serial prostate biopsies. Ancillary radiologic and genomic tests
are investigational but may have a role in patients with discordant clinical and/or pathologic ﬁndings.
Patients who are reclassiﬁed to a higher-risk category (Gleason score $ 7) or who have signiﬁcant
increases in tumor volume on subsequent biopsies should be offered active therapy.
J Clin Oncol 34:2182-2190. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Prostate cancer has the highest incidence rate of
any cancer (233,000 men representing 27% of all
new cases) and the fourth highest mortality rate
(29,480 men representing 10% of all deaths
resulting from cancer) in the United States, even
when considering both sexes.1 For this reason,
there is great interest in deﬁning optimum strategies
for detection, treatment, and follow-up for this
patient population. Even in the absence of a formal
screening program,2 prostate cancer is detected
early in many cases, is indolent or nonprogressing,
and is unlikely to cause morbidity or mortality.3
To avoid the harms associated with unnecessary
treatment, active surveillance (AS) is an option for
patients with prostate cancer that is less likely to
cause mortality. In 2015, Cancer Care Ontario
(CCO) published a Clinical Practice Guideline on
Active Surveillance for theManagement of Localized
Prostate Cancer,4 and the goal of this assessment
was to determine whether to endorse that CCO
guideline.
This American Society of Clinical Oncology
(ASCO) endorsement reinforces the recommen-
dations offered in the CCO guideline on Active
Surveillance for the Management of Localized
2182 © 2016 by American Society of Clinical Oncology
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Prostate Cancer4 and acknowledges the effort put forth by CCO to
produce an evidence-based guideline that informs practitioners
who care for menwith early-stage clinically localized prostate cancer
(stages T1 and T2 and Gleason score # 7).
The following are the ﬁve research questions on the role of AS
in men with localized prostate cancer that were addressed in the
original guideline as well as in this endorsement:
1. How does AS compare with immediate active treatments (e.g.,
RP, RT, brachytherapy, hormone therapy, cryotherapy, or
high-intensity focused ultrasound) as a management strategy
for patients with newly-diagnosed localized prostate cancer
(T1 and T2; Gleason score #7)?
2. In patients with localized prostate cancer undergoing AS,
which ﬁndings of the following tests predict increasing risk of
reclassiﬁcation to a higher-risk disease state? What are their test
characteristics (i.e., positive and negative predictive values,
sensitivities, speciﬁcities, and likelihood ratios)?
• PSA kinetics (e.g., velocity or doubling time)
• DRE
• Imaging (e.g., magnetic resonance imaging [MRI] or
ultrasound [US])
• Prostate cancer antigen3 (PCA3)
3. In patients with localized prostate cancer undergoing AS,
how does supplementation with 5-alpha reductase inhibitors
(5ARIs) (e.g., ﬁnasteride or dutasteride) compare with no
supplementation?
4. In patients with localized prostate cancer undergoing AS, how do
clinical outcomes differ if treatment is managed by a: single doctor
versus a multidisciplinary team of clinicians, urologist versus
another oncologist (e.g., a radiation oncologist), university/
teaching hospital versus a community or private clinic/hospital?
5. In patients with localized prostate cancer who are candidates
for or who are undergoing AS, how does the offer, receipt, or
choice of treatment and patient compliance or adherence
differ based on (but not limited to) the following factors:
• AS protocol: order of and frequency of tests (PSA, DRE,
imaging), and other test/clinical factors?
• Care provider(s): single versus team of doctors; urologist
versus other oncologist?
• Care setting: clinic versus hospital?
• Patient factors: clinical, psychosocial?
• Social support: family or community?
• Socioeconomic or geographic variables?
The original CCO Recommendations are provided in Table 1
and online at http://www.cancercare.on.ca/common/pages/UserFile.
aspx?ﬁleId5325696.
OVERVIEW OF THE ASCO GUIDELINE ENDORSEMENT PROCESS
ASCO has policies and procedures for endorsing practice guidelines that
have been developed by other professional organizations. The goal of
guideline endorsement is to increase the number of high-quality, ASCO-
vetted guidelines available to the ASCO membership. The ASCO
endorsement process involves an assessment by ASCO staff of candidate
guidelines for methodologic quality using the Rigour of Development
subscale of the Appraisal of Guidelines for Research and Evaluation II
instrument (see Methodology Supplement for more detail).
Disclaimer
The clinical practice guidelines and other guidance published
herein are provided by the American Society of Clinical Oncology,
Inc. (“ASCO”) to assist providers in clinical decision making. The
information therein should not be relied on as being complete or
accurate, nor should it be considered as inclusive of all proper
treatments or methods of care or as a statement of the standard of
care. With the rapid development of scientiﬁc knowledge, new
evidence may emerge between the time information is developed
and when it is published or read. The information is not continually
updated and may not reﬂect the most recent evidence. The infor-
mation addresses only the topics speciﬁcally identiﬁed therein and is
not applicable to other interventions, diseases, or stages of diseases.
This information does not mandate any particular course of medical
care. Furthermore, the information is not intended to substitute for
the independent professional judgment of the treating provider
because the information does not account for individual variation
among patients. Recommendations reﬂect high, moderate, or low
conﬁdence that the recommendation reﬂects the net effect of a given
course of action. The use of words like “must,” “must not,” “should,”
and “should not” indicate that a course of action is recommended
or not recommended for either most or many patients, but there is
latitude for the treating physician to select other courses of action
in individual cases. In all cases, the selected course of action should
be considered by the treating provider in the context of treating the
individual patient. Use of this information is voluntary. ASCO
provides this information on an “as is” basis and makes no
warranty, expressed or implied, regarding the information. ASCO
speciﬁcally disclaims any warranties of merchantability or ﬁtness
for a particular use or purpose. ASCO assumes no responsibility
for any injury or damage to persons or property arising from or
related to any use of this information or for any errors or
omissions.
Guideline and Conflicts of Interest
The Endorsement Panel (Appendix Table A1, online only) was
assembled in accordance with ASCO’s Conﬂict of Interest Policy
Implementation for Clinical Practice Guidelines (“Policy” found
at www.asco.org/rwc). All members of the Endorsement Panel
completed ASCO’s disclosure form, which requires disclosure of
ﬁnancial and other interests, including relationships with commercial
entities that are reasonably likely to experience direct regulatory or
commercial impact as the result of promulgation of the guideline.
Categories for disclosure include employment; leadership; stock or
other ownership; honoraria; consulting or advisory role; speakers’
bureau; research funding; patents, royalties, other intellectual
property; expert testimony; travel, accommodations, expenses; and
other relationship. In accordance with the Policy, the majority of
the members of the Endorsement Panel did not disclose any
relationships constituting a conﬂict under the Policy.
ACTIVE SURVEILLANCE GUIDELINE FOR THE MANAGEMENT OF
LOCALIZED PROSTATE CANCER
Clinical Questions and Target Population
The CCO guideline4 addressed ﬁve research questions on the
role of AS in men with localized prostate cancer. The ﬁve research
www.jco.org © 2016 by American Society of Clinical Oncology 2183
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questions asked (1) How does AS compare with immediate active
treatments (eg, RP, RT, brachytherapy, hormone therapy, cryotherapy,
or high-intensity focused US) as a management strategy? (2) Which
of the following tests predict increasing risk of reclassiﬁcation to
a higher-risk disease state: PSA kinetics, DRE, imaging, or PCA3?
(3) How does supplementation with 5ARIs (eg, ﬁnasteride or
dutasteride) compare with no supplementation? (4) How do
clinical outcomes differ if treatment is managed by a single
physician versus a multidisciplinary team of clinicians, a urologist
versus another oncologist, or a university or teaching hospital
versus a community or private clinic or hospital? and (5) How does
the offer, receipt, or choice of treatment and patient compliance or
adherence differ based on (but not limited to) the AS protocol (eg,
the order of and frequency of tests [PSA, DRE, imaging] and other
test or clinical factors), care providers (single physician v a multi-
disciplinary team of clinicians; urologist v other oncologist), care
setting (eg, clinic v hospital), patient factors (eg, clinical, psychosocial),
social support (eg, family or community), and socioeconomic or
geographic variables? The complete set of clinical questions and
corresponding recommendations in the original CCO guideline
are provided in Table 1. The target population for the CCO guideline
is men with early-stage clinically localized prostate cancer (stages
T1 and T2 and Gleason score # 7).
Summary of the Active Surveillance for the
Management of Localized Prostate Cancer Guideline
Development Methodology
The CCO guideline4 was developed by a working group that
included experts in urology, pathology, radiation oncology, and
research methodology. A systematic review of the literature,
covering the years 1996 through 2013 was performed by using the
Ovid MEDLINE and EMBASE databases. In addition, conference
proceedings for the following were also searched for the years 2010
through 2012: ASCOAnnual Meeting, ASCOGenitourinary Cancers
Symposium, AmericanUrological Association, European Association
of Urology, Canadian Urological Association, and American Society
for Radiation Oncology. Details of the search strategies and the
study inclusion criteria and outcomes of interest are available at
http://www.cancercare.on.ca/common/pages/UserFile.aspx?ﬁleId5325696.
The literature search identiﬁed 62 studies eligible for inclusion
in the guideline. The CCO working group reviewed data from
practice guidelines, systematic reviews, randomized controlled
trials, and other comparative studies that reported on AS in males
with newly diagnosed early-stage localized prostate cancer (stages
T1 and T2 and Gleason score # 7) that included 30 or more
patients. The panel provided evidence-based recommendations for
all clinical questions informed by expert consensus.
RESULTS OF THE ASCO METHODOLOGY REVIEW
The methodology review of the CCO guideline4 was completed
independently by two ASCO guideline staff members using the
Rigour of Development subscale from the Appraisal of Guidelines
for Research and Evaluation II instrument. Detailed results of the
scoring for this guideline are available upon request to guidelines@
asco.org. Overall, the Active Surveillance for the Management of
Localized Prostate Cancer guideline scored 6.5 of 7, with a Rigour of
Development score of 98%. The preliminary ASCO content re-
viewers of the Active Surveillance for the Management of Localized
Prostate Cancer guideline, as well as the ASCO Endorsement Panel,
found the recommendations well supported in the original
guideline. Each section, including the guideline recommendations,
the evidentiary base, the development methods, and external
review process, was clear and well referenced in the systematic
review.
This is the most recent information as of the publication date.
For updates and the most recent information and to submit new
evidence, please visit www.asco.org/endorsements/ActiveSurveillance
and the ASCO Guidelines Wiki (www.asco.org/guidelineswiki).
METHODS AND RESULTS OF ASCO UPDATED
LITERATURE REVIEW
ASCO guidelines staff updated the Active Surveillance for the
Management of Localized Prostate Cancer literature search. The
original CCO literature search strategy was rerun using MEDLINE
on March 19, 2015 (for 2012 through February 2015). The search
strategy can be found in the Data Supplement 1. The updated
search yielded 634 records. After reviewing the title and abstract for
each of these hits, 35 were ordered for full text review. Of these,
none were retained for discussion.
RESULTS OF ASCO CONTENT REVIEW
The ASCO Endorsement Panel reviewed the Active Surveillance for
the Management of Localized Prostate Cancer guideline and con-
curred that the recommendations are clear, thorough, and based on
the most relevant scientiﬁc evidence in this content area and present
options that will be acceptable to many patients. Overall, the ASCO
Endorsement Panel agrees with the recommendations as stated in the
guideline, with the minor qualiﬁcations discussed here.
DISCUSSION
The ASCO Endorsement Panel wants to highlight and qualify some
of the statements from the Active Surveillance for the Management
of Localized Prostate Cancer4 guideline.
The distinction between AS and watchful waiting is important
for clinical decision making. AS, which carries a curative intent
and involves regular monitoring with PSA, DRE, and biopsy (see
Recommendation 3), is appropriate for patients who have sufﬁ-
cient life expectancy6 to beneﬁt from active treatment if disease
progression is detected. Note that calculation of life expectancy
is based on a variety of individual factors and circumstances.
A number of life expectancy calculators (eg, http://www.socialsecurity.
gov/OACT/population/longevity.html) are available in the public
domain; however, ASCO does not endorse any one calculator over
another. For patients with a life expectancy of less than 5 years,
watchful waiting (cessation of routine monitoring with treatment
initiated only if symptoms develop) is appropriate and further
reduces the issue of overtreatment in prostate cancer, including
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THE BOTTOM LINE
Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American
Society of Clinical Oncology Clinical Practice Guideline Endorsement
The American Society of Clinical Oncology (ASCO) endorses the Cancer Care Ontario (CCO) guideline on Active Surveillance for the
Management of Localized Prostate Cancer, with qualifying statements (in bold italics).
Guideline Questions
1. How does AS compare with immediate active treatments (e.g., RP, RT, brachytherapy, hormone therapy, cryotherapy, or
high-intensity focused ultrasound) as a management strategy for patients with newly-diagnosed localized prostate cancer
(T1 and T2; Gleason score #7)?
2. In patients with localized prostate cancer undergoing AS, which ﬁndings of the following tests predict increasing risk of
reclassiﬁcation to a higher-risk disease state? What are their test characteristics (i.e., positive and negative predictive values,
sensitivities, speciﬁcities, and likelihood ratios)?
• PSA kinetics (e.g., velocity or doubling time)
• DRE
• Imaging (e.g., magnetic resonance imaging [MRI] or ultrasound [US])
• Prostate cancer antigen3 (PCA3)
3. In patients with localized prostate cancer undergoing AS, how does supplementation with 5-alpha reductase inhibitors
(5ARIs) (e.g., ﬁnasteride or dutasteride) compare with no supplementation?
4. In patients with localized prostate cancer undergoing AS, how do clinical outcomes differ if treatment is managed by a: single
doctor versus a multidisciplinary team of clinicians, urologist versus another oncologist (e.g., a radiation oncologist),
university/teaching hospital versus a community or private clinic/hospital?
5. In patients with localized prostate cancer who are candidates for or who are undergoing AS, how does the offer, receipt, or
choice of treatment and patient compliance or adherence differ based on (but not limited to) the following factors:
• AS protocol: order of and frequency of tests (PSA, DRE, imaging), and other test/clinical factors?
• Care provider(s): single versus team of doctors; urologist versus other oncologist?
• Care setting: clinic versus hospital?
• Patient factors: clinical, psychosocial?
• Social support: family or community?
• Socioeconomic or geographic variables?
Target Population
Men with early clinically localized prostate cancer (stages T1 and T2 and Gleason score # 7)
Target Audience
Clinicians and specialists providing care to patients with prostate cancer (ie, urologists, radiation oncologists, primary care physicians)
Methods
TheASCOEndorsement Panel was convened to consider endorsing the CCOguideline onActive Surveillance for theManagement of Localized
Prostate Cancer that was based on a systematic review of the medical literature. The ASCO Endorsement Panel considered the methodology
used in the CCO guideline by considering the results from the Appraisal of Guidelines for Research and Evaluation II review instrument. The
ASCO Endorsement Panel carefully reviewed the CCO guideline content to determine appropriateness for ASCO endorsement.
ASCO Key Recommendations for Active Surveillance for the Management of Localized Prostate Cancer
ASCO qualifying statements are presented in bold italics. See Table 1 for the original CCO research questions and recommendations.
1. For most patients with low-risk (Gleason score # 6) localized prostate cancer, AS is the recommended disease management
strategy.
ASCO qualifying statement: It is known that there is heterogeneity within this population and therefore factors such as younger age,
high-volume Gleason 6 cancer, patient preference, and/or African American ethnicity should be taken into account in this
recommendation. Young patients (younger than age 55 years) with high-volume Gleason 6 cancer should be closely scrutinized
(continued on following page)
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biopsies which carry a small but nonzero risk of infection and
hospitalization.7
AS is the recommended disease management strategy for
low-risk prostate cancer. Older patients may start on AS,
potentially transition to watchful waiting if there is no disease
progression, and be able to avoid treatment altogether. However,
the ASCO Endorsement Panel recognizes that there is disease
heterogeneity, and select patients with low-risk prostate cancer
may appropriately choose immediate treatment instead of AS,
including patients who are younger, have high-volume Gleason 6
cancer,8 and have African American ethnicity,9 because these
patients have a higher likelihood for disease progression during
their lifetime. A potential drawback to AS is the use of more
intensive treatments when cancer progresses. That is, RT for
intermediate- or high-risk prostate cancer often involves con-
current androgen deprivation therapy or external beam RT with
or without brachytherapy boost; patients who undergo RP with
intermediate- or high-risk cancer may be more likely to need
adjuvant RT. However, this needs to be balanced against the
beneﬁts of AS, including delaying treatment and associated short-
term and long-term adverse effects, and decisions need to take
patient preference into account.
Use of ancillary tests beyond DRE, PSA, and biopsy to improve
patient selection or as part of monitoring in an AS regimen remains
investigational. Although there is a potential for genomic tests10-12 that
use biopsy tissue to predict patients who are more rather than less likely
to have disease progression and cancer-speciﬁc mortality and for
multiparametric magnetic resonance imaging (mpMRI)13 to guide
biopsies to ﬁnd more clinically aggressive disease,14 prospective vali-
dation of these tests is needed to assess their impact on patient outcomes
such as survival. Selective use of these ancillary tests in patients with
discordant clinical and/or pathologic ﬁndings may be appropriate.
There is no clear role for 5ARIs in a routine AS regimen.
5ARIs such as ﬁnasteride and dutasteride block the conversion of
testosterone to dihydrotestosterone.15 A randomized trial compared
dutasteride with placebo in 302 patients undergoing AS for low-
THE BOTTOM LINE (CONTINUED)
for the presence of higher-grade cancer, and deﬁnitive therapy may be warranted for select patients. For patients with limited life
expectancy (< 5 years) and low-risk cancer, watchful waiting may be more appropriate than active surveillance.
2. Active treatment (RP or RT) is recommended for most patients with intermediate-risk (Gleason score 7) localized
prostate cancer. For select patients with low-volume, intermediate-risk (Gleason 3 1 4 5 7) localized prostate
cancer, AS may be offered.
ASCO qualifying statement: Patients with Gleason score 7 (3 1 4) being considered for AS should include only those men with low-
volume Gleason pattern 4 pathology and/or age older than 75 years. Because of known interobserver variability associated with the
identiﬁcation of minor Gleason pattern 4 elements, prospective intradepartmental consultation with colleagues should be considered a
cornerstone of quality assurance in this area. For patients with limited life expectancy (< 5 years), watchful waiting may be more
appropriate than AS.
3. The AS protocol should include the following tests:
• A PSA test every 3 to 6 months
• DRE at least every year
• At least a 12-core conﬁrmatory transrectal ultrasound guided biopsy (including anterior directed cores) within 6 to
12 months, and then serial biopsy every 2 to 5 years thereafter or more frequently if clinically warranted.Men with
limited life expectancy may transition to watchful waiting and avoid further biopsies.
The AS protocol may include ancillary tests that are still under investigation. These could includemultiparametric MRI (mpMRI) and/
or genomic testing. mpMRI and genomic testing may be indicated when a patient’s clinical ﬁndings are discordant with the pathologic
ﬁndings and could be useful in identifying occult cancers or changes indicative of tumor progression in patients at risk. These tests may
also be helpful when the decision regarding AS versus active treatment is uncertain (eg, in cases of low-volume Gleason 31 4). mpMRI
should not be used as a replacement for rebiopsy.
4. For patients undergoing AS who are reclassiﬁed to a higher-risk category, deﬁned by repeat biopsy showing Gleason score$ 7
and/or signiﬁcant increases in the volume of Gleason 6 tumor, consideration should be given to active therapy (eg, RP or RT).
Additional Resources
More information, which may include Data and Methodology Supplements, slide sets, and clinical tools and resources, is available at
www.asco.org/endorsements/ActiveSurveillance and www.asco.org/guidelineswiki. Patient information is available at www.cancer.net.
A link to the Active Surveillance for theManagement of Localized Prostate Cancer guideline can be found at http://www.cancercare.on.
ca/common/pages/UserFile.aspx?ﬁleId5325696.
ASCO believes that cancer clinical trials are vital to informmedical decisions and improve cancer care and that all patients should have
the opportunity to participate.
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risk prostate cancer.16 After 3 years of follow-up, there was no
signiﬁcant difference between the two groups with respect to
pathologic disease progression (deﬁned as increase in either
disease volume and/or Gleason score; 29% dutasteride versus
33% placebo; P 5 .079).17 There was also no difference in
progression to Gleason 7 or higher disease. It should also be noted
that 5ARIs signiﬁcantly alter PSA kinetics, and clinical decisions
regarding rebiopsy in patients taking these medications need to
take this into account. Although the CCO guideline included a
recommendation stating that daily 5ARIs may have a role in men
receiving AS, the ASCO Endorsement Panel chose not to include
this recommendation, because the evidence does not support the
routine use of 5ARIs in this setting.
The ASCO Endorsement Panel was in agreement with the CCO
guideline that there is currently insufﬁcient evidence to make rec-
ommendationswith regard to the personnelwho should be responsible
for the management of AS protocols. However, in the opinion of the
ASCO Endorsement Panel, a multidisciplinary team approach should
be taken when a change to active treatment is considered.
ENDORSEMENT RECOMMENDATION
ASCO endorses all but one recommendation from CCO’s Active
Surveillance for the Management of Localized Prostate Cancer4
guideline published in the Canadian Urological Association Journal,
with qualifying statements.
ADDITIONAL RESOURCES
More information, which may include a Data Supplement, a
Methodology Supplement, slide sets, and clinical tools and resources,
is available at www.asco.org/endorsements/ActiveSurveillance and
www.asco.org/guidelineswiki. Patient information is available at
www.cancer.net. Visit www.asco.org/guidelineswiki to provide
comments on the guideline or to submit new evidence.
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